Program Overview
Eosinophilic esophagitis (EoE) has historically been challenging to evaluate due to the lack of a standardized approach to severity assessment. To address this, AGA convened leading experts to develop the Index of Severity for EoE (I-SEE) tool, which is designed to be easily used in routine practice. In this program, Drs. Evan Dellon, Emily McGowan, and Nirmala Gonsalves demonstrate how to use the I-SEE tool in clinical practice.
Program activities include:
- Level Set Activity: I-SEE: A Novel Clinical Index for Assessing Disease Severity in Eosinophilic Esophagitis
- Morning Commute Podcast: EoE: Picking the Right Tool For the Job
- Morning Commute Podcast: EoE: Why I-SEE Matters, and Evidence To-Date
- Case Videos: I-SEE EoE: Using the App
Supporter Statement
Supported by educational grants from Bristol Myers Squibb and Takeda Pharmaceuticals U.S.A., Inc.
Acknowledgement
Provided by Projects In Knowledge Powered By Kaplan in partnership with the American Gastroenterological Association.
There is no fee for this activity.
Target Audience
Gastroenterologists, pediatric gastroenterologists, allergists, pathologists, advanced practice providers, and other relevant health care professionals
Educational Objectives
- Describe the features measured by the I-SEE clinical index and its role in evaluating eosinophilic esophagitis (EoE) severity.
- Assess the benefits and limitations of various EoE severity assessment tools, including I-SEE.
- Develop EoE monitoring plans based on using optimal measures of disease severity including I-SEE.
Activity Faculty
Chair: Evan S. Dellon, MD, MPH, AGAF
Professor of Medicine
Division of Gastroenterology and Hepatology
Department of Medicine
University of North Carolina School of Medicine
Chapel Hill, North Carolina
Faculty: Nirmala Gonsalves, MD, AGAF, FACG
Professor of Medicine
Division of Gastroenterology and Hepatology
Director of the Northwestern Eosinophilic Gastrointestinal Disorders Program
Northwestern University -- Feinberg School of Medicine
Chicago, Illinois
Faculty: Emily McGowan, MD, PhD
Associate Professor
Department of Internal Medicine and Pediatrics
University of Virginia
Charlottesville, Virginia
Interprofessional Education Committee
Interprofessional Education (IPE) requires collaboration among and between professions in order to enhance skills and strategies for effective health care team practices including communication and coordination of care. In guiding the overall CE Program, the role of the IPE Committee is to improve interprofessional collaborative practice by helping to recognize the different roles, responsibilities, and expertise of other health care professionals to develop team strategies that improve outcomes.
The IPE Committee members include:
Vandana G. Abramson, MD
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee
Jason D. Astrin, DMSc, MBA, PA-C, DFAAPA
Senior Director, Advanced Practice Provider Services
The US Oncology Network
Keller, TX
Ella Balasa
Patient Advocate
Richmond, Virginia
James D. Bowen, MD
Medical Director, Multiple Sclerosis Center
Swedish Neuroscience Institute
Seattle, Washington
Veronica Esquible, PharmD
Clinical Lead Pharmacist
Department of Pharmacotherapy
Swedish Medical Center
Seattle, Washington
Bradley J. Monk, MD, FACS, FACOG
Medical Director, Late Phase Clinical Research
Florida Care Specialists and Research Institute
West Palm Beach, Florida
Brant Oliver, PhD, MS, MPH, APRN-BC
Healthcare Improvement Scientist
Associate Professor
The Dartmouth Institute & Geisel School of Medicine at Dartmouth
Hanover, New Hampshire
Ilon S. Rincon Portas, MD
Executive Director
Kaplan Medical Prep
Kaplan North America
Fort Lauderdale, Florida
Katherine Sibler, MSN, WHNP-BC
Nurse Practitioner
Vanderbilt Breast Center
Nashville, Tennessee
Midwest
If you missed our Midwest workshop, join us in-person or virtually at one of our remaining locations.
University of Chicago
Gleacher Center
Feb. 24, 2024
Course directors:
Northeast
If you missed our Northeast workshop, join us in-person or virtually at one of our remaining locations.
University of Pennsylvania
Jordan Medical Education Center - Law Auditorium
Jan. 20, 2024
Course directors:
Joint Accreditation Statement
In support of improving patient care, Projects In Knowledge® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME/CE Instructions
To obtain CME/CE credit:
Read or listen to each activity carefully.
Complete/submit each posttest and evaluation.
A record of your participation will be available in the CME Tracker and the certificate will be available on our website.
Disclosure Information
Projects In Knowledge® adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests)*. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Evan S. Dellon, MD, MPH, AGAF, has been a consultant for AbbVie, Inc, Adare Pharma/Ellodi Pharmaceuticals, Akeso Biopharma, Alfasigma USA, Inc., ALK, Allakos Inc., Amgen Inc., Apollo Therapeutics, Aqilion, Arena Pharmaceuticals/Pfizer Inc., Aslan Pharmaceuticals, AstraZeneca, AVIR Pharma, BioCryst, Bryn Pharma, Calypso Biotech, Celgene Corporation/Receptos/Bristol Myers Squibb, Celldex Therapeutics, Dr. Falk Pharma, EsoCap Biotech, Eupraxia Pharmaceuticals, Ferring Pharmaceuticals, GlaxoSmithKline, Holoclara, Invea Therapeutics, Knightpoint, Lucid Diagnostics, Morphic Therapeutic, Nexstone Immunology/Uniquity Bio, Nutricia, Parexel/Calyx, Phathom Pharmaceuticals, Regeneron Pharmaceuticals, Revolo Biotherapeutics, Robarts Research Institute/Alimentiv, Sanofi, Shire/ Takeda Pharmaceuticals U.S.A., Inc., Target RWE, and Upstream Bio; has received research funding from Adare Pharma/Ellodi Pharmaceuticals, Allakos Inc., Arena Pharmaceuticals/Pfizer Inc., AstraZeneca, Celldex Therapeutics, Eupraxia Pharmaceuticals, Ferring Pharmaceuticals, GlaxoSmithKline, Meritage Pharma, Miraca Life Sciences, Nutricia, Celgene Corporation/Receptos/Bristol Myers Squibb, Regeneron Pharmaceuticals, Revolo Biotherapeutics, Sanofi, and Shire/Takeda Therapeutics; and has received educational grants from Allakos Inc., Aqilion, Holoclara, and Invea Therapeutics.
Nirmala Gonsalves, MD, AGAF, FACG, has been a consultant for AstraZeneca, Bristol Myers Squibb, Exact Sciences, Eupraxia Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.; has been a speaker for Regeneron Pharmaceuticals, Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.; and has authored a chapter for UpToDate.
Emily McGowan, MD, PhD, has served on an advisory board for Bristol Myers Squibb; has served on two advisory boards for Takeda Pharmaceuticals U.S.A., Inc.; and has provided educational content about multi-D clinics for EoE for Regeneron Pharmaceuticals.
Peer Reviewer has no relevant financial relationships to disclose.
Vandana G. Abramson, MD (IPE Committee) has no relevant financial relationships to disclose.
Jason D. Astrin, DMSc, MBA, PA-C, DFAAPA (IPE Committee) has no relevant financial relationships to disclose.
Ella Balasa, Patient Advocate (IPE Committee), has been a content creator for Health Union; and has been on the patient advisory board for Genentech, A Member of the Roche Group, Health Union, Medidata, Parexel, and ZS Consulting.
James D. Bowen, MD (IPE Committee), has received honoraria from Biogen, EMD Serono, Inc., Genentech, and Novartis; has received consulting fees from Biogen, Celgene, EMD Serono, Genentech, a Member of the Roche Group, and Novartis Pharmaceuticals Corporation; has conducted contracted research for Alexion Pharmaceuticals, Inc, Alkermes, Biogen, Celgene Corporation, Genentech, a Member of the Roche Group, Genzyme, Novartis Pharmaceuticals Corporation, and TG Therapeutics, Inc; and has ownership interest in Amgen Inc.
Veronica Esquible, PharmD (IPE Committee), has no relevant financial relationships to disclose.
Bradley Monk, MD, FACOG, FACS (IPE Committee), has received consulting fees from AbbVie, Inc, Advaxis, Inc., Agenus Inc., Amgen Inc., Aravive, Inc., Asymmetric Therapeutics, Boston Biomedical, Chemocare, ChemoID, Circulogene, Conjupro Biotherapeutics Inc, Eisai Co., Ltd, Geistlich Pharma North America, Inc., Genmab/Seattle Genetics, GOG Foundation, Immunomedics, Inc., ImmunoGen, Inc., Incyte Corporation, Laekna Healthcare Private Limited, Mateon Therapeutics, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Mersana Therapeutics, Inc., Myriad Genetics, Nucana, OncoMed Pharmaceuticals, OncoQuest Inc., OncoSec Medical Inc, Perthera Inc., Pfizer Inc., Precision Oncology, Puma Biotechnology Inc, Regeneron Pharmaceuticals, Samumed, LLC, Takeda Pharmaceutical Company, Ltd, VBL Therapeutics, and Vigeo Therapeutics; and has been a Speaker/Consultant for AstraZeneca, Clovis Oncology, F. Hoffmann-La Roche Ltd/ Genentech, A Member of the Roche Group, Janssen Pharmaceuticals/Johnson & Johnson, Inc., and Tesaro, Inc/GlaxoSmithKline.
Brant Oliver, PhD, MS, MPH, APRN-BC (IPE Committee), has conducted contracted research for Biogen and EMD Serono.
Ilon S. Rincon Portas, MD (IPE Committee), has no relevant financial relationships to disclose.
Katherine Sibler, MSN, WHNP-BC (IPE Committee), has no relevant financial relationships to disclose.
Projects In Knowledge staff members have no relevant financial relationships to disclose.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
*An ineligible company (commercial interest) is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used, on patients.
Off-Label Drug Statement: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.